Alerta

HODGKIN LYMPHOMA THERAPY

Resumen de: US20260034102A1

There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof:a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.

MULTI-CYCLIC IRAK1 AND IRAK4 INHIBITING COMPOUNDS AND USES THEREOF

Resumen de: US20260034112A1

The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAK1 and IRAK4. The present disclosure further provides a method of determining a compound that is effective at treating an inflammatory disease/disorder, AML, or MDS.

PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA, AND METHOD FOR SCREENING ACTIVE INGREDIENT THEREOF

Resumen de: WO2026029193A1

The present disclosure provides a leukemia therapeutic agent and a method for screening an active ingredient thereof. The leukemia therapeutic agent according to the present disclosure contains an IMPDH1 inhibitor as an active ingredient. The method for screening the active ingredient of the leukemia therapeutic agent comprises a step for selecting, from among a group of compounds to be tested, a compound that exhibits, with respect to leukemia cells, (I) IMPDH inhibitory effect and/or (II) at least one effect selected from the group consisting of (1) to (5): (1) IRBC induction effect, (2) IRBCC formation effect, (3) TP53 protein stabilization effect, (4) TIGAR induction effect, and (5) MYC transcriptional suppression effect.

MICROCRYSTALLINE POLYMORPHS OF LMP400 AND USES THEREOF

Resumen de: WO2026029971A1

Disclosed herein are crystalline polymorphs of indotecan (LMP400) that can be used in the treatment of cancers associated with dysregulation of Topl and/or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a. glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

MICROCRYSTALLINE POLYMORPHS OF LMP744 AND USES THEREOF

Resumen de: WO2026029972A1

Disclosed herein are crystalline polymorphs of LMP744 that can be used in the treatment of cancers associated with dysregulation of Top1 and/or MYC activity, such as, for example, a sarcoma, (e.g., Ewing's sarcoma), a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, a melanoma, a glioma, leukemia, a lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching m the particular art and is not intended to be limiting of the present invention.

SIRNA FOR INHIBITING KRAS GENE EXPRESSION, AND MODIFIED FORM THEREOF AND USE THEREOF

Resumen de: WO2026026715A1

The present application belongs to the field of biomedicine. Disclosed are an siRNA for inhibiting KRAS gene expression, and a modified form thereof and the use thereof. Provided in the present application is a double-stranded RNA molecule targeting KRAS, wherein the molecule can treat KRAS-associated diseases such as metastatic non-small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, KRAS G12C+ non-small cell lung cancer, diabetic retinopathy, leukemia, cholangiocarcinoma, metastatic colorectal cancer, gastric cancer, advanced non-small cell lung cancer, stage-IV non-small cell lung cancer, gastric adenocarcinoma, sepsis, KRAS G12C-mutated advanced non-small cell lung cancer and gallbladder cancer.

DOSAGE REGIMEN FOR REDUCING CYTOKINE RELEASE SYNDROME (CRS) WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA THERAPY

Resumen de: WO2026030464A1

The disclosure provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CDS) bispecific antibodies (e.g., cevostamab).

DARATUMUMAB.BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR TREATING MULTIPLE MYELOMA

Resumen de: WO2026028164A1

The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.

METHODS FOR TREATING HIGH-RISK SMOLDERING MULTIPLE MYELOMA

Resumen de: WO2026028163A1

Described herein are methods and compositions for treating high-risk smoldering multiple myeloma in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-CD38 antibody.

METHODS OF USE OF MULTI-SPECIFIC BINDING PROTEINS

Resumen de: MX2025011964A

Provided herein are anti-CD19 antibodies and multi-specific binding proteins that bind CD19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers including relapsing and/or refractory Non-Hodgkins Lymphoma, and cancers that express low levels of CD19.

ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF

Resumen de: MX2025011898A

Aspects of the disclosure provide anti-TMPRSS6 antibodies and methods of using the same for promoting hepcidin expression, and treating iron overload associated conditions, such as hemochromatosis, sickle cell disease, thalassemia, hemolysis, Diamond-Blackfan anemia, myelodysplastic syndrome (MDS), blood transfusion.

IRAK INHIBITOR FREE BASE, SALTS, AND POLYMORPHIC FORMS THEREOF

Resumen de: MX2025012730A

The present disclosure provides crystalline free base and salts of an imidazo1,2- bpyridazine compound. In some embodiments, the crystalline imidazo1,2-bpyridazine compound is a single crystal. The present disclosure also provides methods of using the crystal forms to treat certain diseases or disorders. Some embodiments include methods of using the crystal forms to treat hematopoietic cancers, myelodysplastic syndromes (MDS), or acute myeloid leukemia (AML). Additional embodiments provide disease treatment using the crystal forms in combination with other therapies, such as cancer therapies.

METHODS FOR TREATING MULTIPLE MYELOMA

Nº publicación: MX2025012460A 03/02/2026

Solicitante:

JANSSEN BIOTECH INC [US]
JANSSEN BIOTECH, INC

Resumen de: MX2025012460A

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a bi-weekly dosing schedule.